Wnt5a induces ROR1 signaling in CLL. Wnt5a engagement of ROR1 results in a signaling pathway that recruits DOCK2, leading to Rac1/2 signaling and increased proliferation. However, DOCK2 knockdown using siRNA reduces protein expression and consequently its binding to the PRD, leading to reduced Rac1/2 and proliferation. Similarly, blocking Wnt5a signaling with cirmtuzumab prevents DOCK2 recruitment to the PRD and prevents Rac1/2 activation and proliferation.